What's Sculptra And Why Does This Substance Improve Your Look?
| by Dr Mart Ooi | July 25, 2008
This article will explain what Sculptra is and exactly how it functions to make you look younger.
Poly-1-lactic acid (PLLA), a.k.a. Sculptra, received FDA approval in 2004 for the treatment of AIDS-mediated facial fat atrophy. It's injected into the subcutis and encourages skin cell replication. A number of injections are required, but the cosmetic end-effects for sunken cheek have been impressive. In the Europe-based studies, the effect remained for 18-24 months. Esthetic use of this substance is considered off-label, but has been utilized for pan facial augmentation. It's very important to inject this filler in the correct plane. Injection into the dermis will heighten the risk of granuloma formation.
Here's how Sculptra works.
Dissolution of fat on the face causes dramatic changes in appearance and may be caused by hereditary syndromes, disease or aging. In natural aging, it happens by way of loss of elasticity, collagen breakdown and bony reabsorption. This deflation due to volume loss causes further skin redundancy.
A few classes of fat atrophy depending upon anatomic considerations have been reported. Trying to correct by tightening the skin without addressing volume replacement leads to a sunken look. Volume replenishment has been achieved by a wide variety of naturally-found (hyaluronic acid, collagen, fat) and synthetic (acrylates, silicone and other polymers) fillers, both biodegradable (meaning that they can be broken down by the body) and permanent. Poly-L-lactic acid (PLLA), marketed in United States Of America and Europe as Sculptra, is a new type of fibroplastic fillers whose 'bulking effect' depends upon host response.
Injectable PLLA, a.k.a. Sculptra, is a biocompatible, reabsorbable polymer that triggers a purposeful inflammatory response to foreign body, regeneration of skin cells and a slow metabolic breakdown of the polymer microspheres. Histological and clinical trials indicate long-term results, that may last for longer than 2 years. At the current time, Poly-L-lactic acid is FDA-approved solely for the purpose of AIDS-mediated fat atrophy, and all other usage are 'off-label', though double-blind clinical studies for aesthetic usage are now almost done. A number of documentations recapitulate the biological end products and treatment of fat atrophy with Sculptra.
Poly-1-lactic acid (PLLA), a.k.a. Sculptra, received FDA approval in 2004 for the treatment of AIDS-mediated facial fat atrophy. It's injected into the subcutis and encourages skin cell replication. A number of injections are required, but the cosmetic end-effects for sunken cheek have been impressive. In the Europe-based studies, the effect remained for 18-24 months. Esthetic use of this substance is considered off-label, but has been utilized for pan facial augmentation. It's very important to inject this filler in the correct plane. Injection into the dermis will heighten the risk of granuloma formation.
Here's how Sculptra works.
Dissolution of fat on the face causes dramatic changes in appearance and may be caused by hereditary syndromes, disease or aging. In natural aging, it happens by way of loss of elasticity, collagen breakdown and bony reabsorption. This deflation due to volume loss causes further skin redundancy.
A few classes of fat atrophy depending upon anatomic considerations have been reported. Trying to correct by tightening the skin without addressing volume replacement leads to a sunken look. Volume replenishment has been achieved by a wide variety of naturally-found (hyaluronic acid, collagen, fat) and synthetic (acrylates, silicone and other polymers) fillers, both biodegradable (meaning that they can be broken down by the body) and permanent. Poly-L-lactic acid (PLLA), marketed in United States Of America and Europe as Sculptra, is a new type of fibroplastic fillers whose 'bulking effect' depends upon host response.
Injectable PLLA, a.k.a. Sculptra, is a biocompatible, reabsorbable polymer that triggers a purposeful inflammatory response to foreign body, regeneration of skin cells and a slow metabolic breakdown of the polymer microspheres. Histological and clinical trials indicate long-term results, that may last for longer than 2 years. At the current time, Poly-L-lactic acid is FDA-approved solely for the purpose of AIDS-mediated fat atrophy, and all other usage are 'off-label', though double-blind clinical studies for aesthetic usage are now almost done. A number of documentations recapitulate the biological end products and treatment of fat atrophy with Sculptra.
Article Source: http://www.articleset.com
You are welcome to publish or reprint this article free of charge, provided:
- you include the entire article, unchanged, including the "About The Author" box
- all hyperlinks remain active, including the bottom ArticleSet.com link (does not apply to print publications)
- you agree not to hold the authors nor ArticleSet.com liable for any loss profits, expenses, or any other damages resulting from the use or misuse of articles published on this website
Menu
Home Top ArticlesTop AuthorsSubmit ArticleArticleSet BlogLink To UsArticle FeedsTermsContactFeatured
Back Pain Relief Jacksonville Health Community on Hospitals Causes of ADHD Monavie acai juice Green laser pointerLanguage
